Pharma company Sensidose has recruited Philip Slätis as Chief Operating Officer and Deputy CEO. Slätis takes on on his role on November 1 and brings broad experience from the pharmaceutical industry. He is expected to contribute to the company’s business development and continued expansion with Flexilev for individualized treatment of Parkinson’s disease in the advanced phase, the so-called wearing-off stage.

Read the whole article on Biostock’s website